Market Access, Value, and Reimbursement Resources

Digital health has grown and evolved rapidly in the past decade—spurred by exciting developments in AI, machine learning, and the internet of things (IoT), alongside nearly ubiquitous adoption of smar

Independent talent provide an agile source of critical skills that allow life science leaders to keep pace in a fast-changing environment.

How can pharma marketers remain effective and relevant for key customers, patients, and healthcare providers (HCPs) in the time of COVID-19?

On-demand talent is a critical resource for life science and pharma companies as they innovate to keep pace with market changes, respond to emerging health threats, and adapt to a remote environment.

In an effort to inform its Rare Diseases commercial strategy within a specific country, an F100 pharmaceutical company was looking to gain a deeper understanding of the current competitive...

As a part of its global therapeutic area (TA) health policy initiatives, a leading biopharma company needed a new and improved narrative and evidence deck to impress upon policymakers and other...

An F500 biotech company wanted to engage a consultant to work with its medical evidence, research, and innovation team to create and coordinate several projects related to the generation of...

The U.S. patient access team at an F200 biopharma leader was seeking a strong project manager who would support their market access and marketing teams with patient / HCPs promotions. The client...

In the midst of a company-wide reorganization, the Cell Therapy Market Access team at an F200 pharmaceutical company needed a value and access expert to support several projects. Looking for...

The pharmaceutical reimbursement landscape has grown increasingly complex and—thanks to an intensifying focus on improving clinical outcomes—increasingly competitive. Reimbursement was once a...

Independent consultants provide fast, efficient, and cost-effective support for market access initiatives in health economics, pricing, regulations, patient engagement, and communications.

Prescription drug affordability is a major concern in health and life science. Asif Velani and Will Wright talk about how to address it.

Affordability is a major concern in health and life science—and not just in the U.S. In 2018, total prescription drug expenditure in the U.S. is expected to top $520 billion; 52% of Americans say...

The lines are blurring between U.S. healthcare payers and providers. What does this payer/provider consolidation mean for pharma? Nothing less than a total shift in the way it does business. If...

A major biopharmaceutical company had developed a breakthrough medication that stood to dramatically disrupt the market for its therapeutic area. Expected to be approved by the FDA in the next...

It can be hard to find the right talent to manage critical initiatives—especially when trying to find a life science consultant. In the life science industry, 70% of CEOs say they are concerned...